Randomized Trial of Therapy of Early Phase Chronic Myelogenous Leukemia With High-Dose Imatinib Mesylate (Gleevec) Alone or in Combination With Peg-Alpha Interferon (PEG-Intron) and Sargramostin (GM-CSF).
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2016
At a glance
- Drugs Imatinib (Primary) ; Peginterferon alfa-2b; Sargramostim
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 06 Dec 2016 Results from this and other five studies presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 18 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.